Drugs online research references
Contracept Technol Update. 1987 Sep;8(9):113.
Survey shows practice sites prefer ON 7/7/7 for new patients.
[No authors listed]
PIP: The 1987 survey of preferences in pill prescription for new patients by subscribers to Contraceptive Technology Update showed that the degree of popularity of the triphasic ON 7/7/7 varied slightly by the type of practice setting. Over 75% of Planned Parenthood clinicians preferred ON 7/7/7, reflecting contracts with Ortho Pharmaceuticals. Fifty-nine percent of both public health clinics and independent clinics chose ON 7/7/7 as first choice. Similarly, 58% of college clinics preferred ON 7/7/7. The proportion of doctors in private practice choosing ON 7/7/7 was just over half. Second choices were ON 1/35 by Planned Parenthood and public health clinics, Triphasil by private physicians, Trinorinyl by college clinics, and a close tie for ON 1/35, Triphasil and Trinorinyl by independent clinics.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12268911&dopt=Abstract
word match triphasil online literature
Eur J Obstet Gynecol Reprod Biol. 1993 Jan;48(1):43-50.
Inflammatory reaction in endometriotic tissue: an immunohistochemical study.
Cirkel U, Ochs H, Mues B, Zwadlo G, Sorg C, Schneider HP.
Department of Obstetrics and Gynecology, University of Munster, Germany.
A panel of monoclonal antibodies specific for macrophage subtypes appearing in early (27E10), down-regulatory (RM3/1) and late (25F9) stages of inflammation had been applied to 20 endometriotic implants of 14 women. Of those patients 9 were in the follicular phase of the cycle, two on danazol, one on LHRH-analogue (buserelin) and another two on oral contraceptives. Beside the macrophage subsets, antibodies against T4, T8 lymphocytes as well as proliferating cells (EN7/44 and Ki67) were examined. In all specimens immunologically competent cells could be detected to a varying degree and within the same implant different stages of inflammation were discernible. Endometriosis presented with signs of early inflammation indicated by 27E10+ macrophages and CD4+ lymphocytes (15 specimens) and with down-regulatory, late inflammatory reactions as shown by RM3/1+, 25F9+ macrophages and CD8+ lymphocytes (19 biopsies). Additionally, in 14 specimens cells of the EN7/44+ and Ki67+ type was detected. These preliminary results showed no significant correlation to either extension of endometriotic implants or adhesions or concomitant therapy and clearly indicate, that there is an immunological dynamic process within the lesion itself in addition to that one of the peritoneal fluid.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8449261&dopt=Abstract
word match triphasil online literature
Contracept Technol Update. 1985 Jan;6(1):1-2, 4.
Three triphasic oral contraceptives now available in U.S.
[No authors listed]
PIP: The 3 triphasic oral contraceptives currently marketed in the US are describes in reference to steroid composition and manufacturers claims concerning the reduced side affects associated with the triphasics. These triphasics are 1)Ortho-Novum 7-7-7, producted by the Ortho Pharmaceutical Corporation; 2) Tri-Norinyl, produces by Syntex; and 3)Triphasil, produced by Wyeth Laboratries. The 1st 2 formulations were approved by the Food and Drug Administration (fda) in early 1984, andd Triphasil was approved in December, 1984. Despite the recency of triphasic availability, a survey of 13 family planning clinicians, conducted by Contraceptive Technology Update, revealrd that triphasics were the 2nd most common type of OC prescribed by the clinicians. All 3 triphasics provide varying daily doses of progestogen throughout the cycle but only Triphasil varies the daily dose of estrogen. Triphasil provides a total progestogen dose of 1.925 mg of levonor estrel for the entire cycle, and a daily dose of 0.05 mg for 6 days, 0.075 mg for 5 days, and 0.125 mg for 10 days. The total dose of ethinyl estradiol provides by Triphasil is 700 mcg, and the daily dose is 30 mcg for 6 days, 40 mcg for 5 days, and mcg for 10 days. Tri-Norinyl provides a total progedtogen dose of 15.0 mg ofnorethindine at a daily dose of 0.5 mg for 7 days, 1.0 mg for & days, anf 0.5 mg for 5 days. The total ethinyl estradiol dose is 735 mcg provided at a constant rate of 35 mcg for 21 days. Ortho-Novum 7-7-7 provides a total progestogen dose of 15.75 mg of norethindrone at a rate of 0.5 mg for 7 days, 0.75 mg for 7 days, and 1.0 mg for 7 days. The total dose of ethinyl estradiol is 735 mcg provided at a constant rate of 35 mcg/day for 21 days. The triphasics provide low steriod dosages in order to minimize longterm adverse effects; however, unlike other low dose formulations, the triphasics, according to the manufacturers, are associated with only minimal breakthrough bleeding problems. Ortho claims women who use Otrho-Novum 7-7-7 have bleeding patterns similar to those associated with Ortho-Novum 1-35 by the end of the 3rd menstrual cycle. Syntex claims that the incidence of breakthrough bleeding, amenorrhea, weight gain, headachess, nausea, and edema among women who use Tri-Norinyl is similar to that observed among women who use Norinyl 1-35. Wyeth reported that among women who took Triphasil for 25 montha, the total incidence of breakthrough bleeding was only 5.7%. The cost of the triphasics is similar to the cost of other low dose OCs, and the reiphasics are reportedly as effective as the higher dose OCs.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12279912&dopt=Abstract
word match triphasil online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||